PMID- 19888412
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20091214
LR  - 20231103
IS  - 1932-2968 (Electronic)
IS  - 1932-2968 (Linking)
VI  - 1
IP  - 2
DP  - 2007 Mar
TI  - Prospects and challenges for islet regeneration as a treatment for diabetes: a 
      review of islet neogenesis associated protein.
PG  - 231-44
AB  - Diabetes mellitus results from inadequate insulin action, which can be viewed as 
      a consequence of the limited ability to restore beta cells after they are lost as 
      the result of metabolic exhaustion, autoimmune destruction, or surgical insult. 
      Arguably, a uniformly effective therapeutic pathway to address all forms of 
      diabetes would be to reverse the restrictions on beta-cell and islet 
      regeneration. The development from progenitor cells of islets with normal 
      endocrine function does occur in adult humans; it is referred to as islet 
      neogenesis. The induction of islet neogenesis is an important, if not essential, 
      therapeutic approach for curing type 1 diabetes mellitus (T1DM) and could be 
      valuable in the treatment of type 2 diabetes mellitus (T2DM) as well. Islet 
      neogenesis associated protein (INGAP) is the first therapeutic candidate to be 
      identified as the result of a purposeful search for an endogenous molecule with 
      islet neogenic activity. It was found that partial obstruction of the pancreatic 
      duct in hamsters induced islet neogenesis; under this condition, a 
      neogenesis-promoting activity was identified and partially purified from a 
      soluble tissue fraction. A 168-kDa protein product of the cloned gene was found 
      to be responsible for the neogenesis activity. This molecule named INGAP contains 
      an active core sequence of amino acids called INGAP peptide. Results from in 
      vitro, animal, and human studies suggest that INGAP and INGAP peptide are 
      neogenic in at least several vertebrate species, including humans. INGAP has 
      since been found to be a member of the family of Reg proteins, which are found 
      across and in multiple versions within species and are closely associated with 
      embryonic and regenerative processes. Clinical results suggest that INGAP peptide 
      can be a suitable neogenesis therapy, but optimization of the therapy and more 
      data are required to fully access this potential. Understanding of the signaling 
      pathways of INGAP and other related Reg proteins is a promising means of 
      advancing therapeutic development for people with T1DM and T2DM. The quest for 
      the fundamental restorative approach to lost insulin secretion is an enticing 
      target for drug development.
FAU - Fleming, Alexander
AU  - Fleming A
AD  - Kinexum Metabolics, Inc., Harpers Ferry, West Virginia, USA.
FAU - Rosenberg, Lawrence
AU  - Rosenberg L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Diabetes Sci Technol
JT  - Journal of diabetes science and technology
JID - 101306166
PMC - PMC2771469
OTO - NOTNLM
OT  - INGAP
OT  - Reg
OT  - diabetes
OT  - islet neogenesis
OT  - pancreatic plasticity
OT  - regeneration
EDAT- 2007/03/01 00:00
MHDA- 2007/03/01 00:01
PMCR- 2008/03/01
CRDT- 2009/11/06 06:00
PHST- 2009/11/06 06:00 [entrez]
PHST- 2007/03/01 00:00 [pubmed]
PHST- 2007/03/01 00:01 [medline]
PHST- 2008/03/01 00:00 [pmc-release]
AID - dst.1.2.0231 [pii]
AID - 10.1177/193229680700100214 [doi]
PST - ppublish
SO  - J Diabetes Sci Technol. 2007 Mar;1(2):231-44. doi: 10.1177/193229680700100214.